About me
Feisal Othman is a drug safety and benefit–risk assessment professional with over 15 years of experience across healthcare, patient safety, and regulatory science. He currently serves as a Benefit Risk Assessment Lead at Bristol Myers Squibb, where he leads the development and application of structured benefit–risk assessment methodologies across the product lifecycle. His experience includes global risk management strategy development, REMS, regulatory engagement, and cross-functional leadership. Feisal holds a Doctor of Pharmacy degree from Midwestern University and a Bachelor of Science from the University of Illinois at Chicago.
